Eric Lefkofsky, with an estimated net worth close to $4 billion, is a serial entrepreneur known for making multiple companies public. He’s best recognized for co-founding Groupon, which went public in 2011 with a valuation of around $13 billion. Now, Lefkofsky is preparing Tempus AI Health, a genomic testing and data analysis startup, for its IPO.
What is Tempus and Why is It Important?
Founded in 2015, Tempus aims to revolutionize cancer treatment through genomic testing and data analysis. Inspired by his wife’s successful battle with breast cancer, Lefkofsky created Tempus to integrate advanced data technology into healthcare.
How Did Groupon’s IPO Influence Lefkofsky’s Reputation?
Groupon’s IPO was one of the most well-known debuts of 2011, but it was also fraught with issues. Lefkofsky was accused of misappropriating over $300 million from Groupon’s pre-IPO funding, leading to significant financial scrutiny and controversy. Despite this, his ventures have garnered significant attention and investment.
What Were the Outcomes of Lefkofsky’s Other Ventures?
InnerWorkings (2006): A supply chain firm that went public smoothly and was later sold to private equity in 2021.
Echo Global Logistics (2009): A logistics company that saw steady stock appreciation and was sold to private equity in 2021 at a 50% premium.
What Are the Financial Highlights of Tempus?
Revenues for Tempus increased from $321 million in 2022 to $531 million in 2023. However, the company is still facing substantial losses, with net losses of $290 million in 2023 and $214 million in 2022. Despite these losses, the operating loss margin improved significantly, dropping from 83% in 2022 to 37% in 2023.
How Does Lefkofsky Plan to Maintain Control Over Tempus?
Lefkofsky holds significant sway at Tempus, intending to maintain control through super-voting shares. Each of his shares has thirty votes, a notably high number compared to the typical ten votes seen in similar arrangements.
What Role Does Pathos AI Play in Tempus’s Strategy?
Tempus has a contract with Pathos AI health, a drug discovery platform also founded by Lefkofsky. Pathos compensates Tempus for the use of its data. Ryan Fukushima, Tempus’s COO, also serves as the CEO of Pathos, managing responsibilities between both companies.
What Are the Financial Compensations and Benefits for Lefkofsky?
Despite not receiving a salary for the past two years, Lefkofsky is set to receive a bonus of $800,000 starting in 2025. Additionally, he received a $5.3 million dividend from business stock and $200,000 for private jet expenses. Tempus also paid $7.5 million for preferred shares issued to him.
What Challenges Does Tempus Face in Its IPO?
Tempus’s S-1 filing highlights that the company is still far from breaking even and will need to raise additional capital in the future. Investors may be concerned about the potential for follow-on public offerings, which could impact the share price negatively.
How Is Tempus Positioned in the AI and Healthcare Market?
Tempus is positioning itself as an AI-driven company, though its AI-related revenue was only $5.5 million in 2023, about 1% of its total revenue. The company plans to embed AI, including generative AI health, into all aspects of its diagnostic tools.
What Do Investors Think About Tempus’s AI Strategy?
A healthcare venture capitalist noted that Tempus might be banking on the growing interest in AI within life sciences. However, the company has yet to prove its capabilities in this area fully. The AI health product line is still in its early stages, according to the S-1 filing.
Who is Eric Lefkofsky?
Eric Lefkofsky is a serial entrepreneur known for founding multiple companies, including Groupon, and preparing them for IPOs.
What is Tempus?
Tempus is a genomic testing and data analysis startup founded by Lefkofsky in 2015, aiming to integrate advanced AI health data technology into cancer care.
What controversies surrounded Groupon’s IPO?
Groupon’s IPO was controversial due to allegations of Lefkofsky misappropriating pre-IPO funds and significant financial scrutiny during its initial S-1 filings.
How does Lefkofsky plan to control Tempus?
Lefkofsky holds super-voting shares with thirty votes each, ensuring significant control over Tempus after it goes public.
What are Tempus’s financial highlights and challenges?
Tempus’s revenues grew significantly, but the company still faces substantial losses. It plans to raise additional capital post-IPO, which may affect its share price.
